Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | HK1 | P19367 | 1/20 | 0.36 |
| ▸ | HK2 | P52789 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | F11 | P03951 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447620 | 0.88 | F10 (0.39) | F10ACKR3F2F11MAPK1 | |
| SCHEMBL3448349 | 0.87 | F10 (0.43) | F10ACKR3F2F11MAPK1 | |
| SCHEMBL3450355 | 0.86 | F10 (0.41) | F10ACKR3F2F11MAPK1 | |
| SCHEMBL3447699 | 0.86 | F10 (0.39) | F10ACKR3F2F11MAPK1 | |
| SCHEMBL3450031 | 0.85 | F10 (0.47) | F10ACKR3F2F11MAPK1 | |
| SCHEMBL3447739 | 0.84 | ACKR3 (0.39) | F10ACKR3F2F11 | |
| SCHEMBL3449216 | 0.83 | F10 (0.47) | F10ACKR3F2F11MAPK1 | |
| SCHEMBL3448176 | 0.81 | F10 (0.40) | F10ACKR3F2F11MAPK1 | |
| SCHEMBL3448418 | 0.81 | F10 (0.42) | F10ACKR3F2F11 | |
| SCHEMBL3449111 | 0.80 | F10 (0.39) | F10ACKR3F2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1877404-A2 | NOVEL CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-20060247238-A1 | Cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247238-A1 | Cyclic amines | F12, F11, F2 | F10 4/4885ACKR3 568/4885HK1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.